Eloxx Pharmaceuticals financials
$15.42+2.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 | Q2 '23 Jun 30 | Q1 '23 Mar 31 | Q4 '22 Dec 31 | Q3 '22 Sep 30 | Q2 '22 Jun 30 | Q1 '22 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | $0.00 | — | — | — | $0.00 | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | $0.00 | — | — | — | $0.00 | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$4.5M | -$3.8M | -$1.6M | -$1.2M | — | -$3.6M | -$4.1M | -$5.5M | -$6.0M | -$7.1M | -$10.3M | -$11.0M |
| Net income | -$4.5M | -$3.8M | -$1.9M | -$1.7M | — | -$3.6M | -$4.3M | -$6.2M | -$6.3M | -$7.5M | -$10.6M | -$11.6M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.66 | $-0.08 | $-5.45 | $-0.45 | — | $-1.31 | $-1.96 | $-2.88 | $-16.31 | $-3.47 | $-4.90 | $-5.36 |
| EBITDA | -$4.5M | -$3.8M | -$1.6M | -$1.2M | $0.00 | -$3.4M | -$4.0M | -$5.3M | -$5.8M | -$7.0M | -$10.2M | -$10.8M |
| Operating cash flow | -$4.8M | -$5.5M | -$1.8M | $1.2M | — | -$3.5M | -$2.1M | -$6.8M | -$5.7M | -$6.9M | -$9.7M | -$9.5M |
| Free cash flow | -$4.8M | -$5.5M | -$1.8M | $1.2M | — | -$3.5M | -$2.1M | -$6.8M | -$5.7M | -$7.0M | -$9.8M | -$9.5M |
| Diluted shares | 6.8M | 48.2M | 0.3M | 3.8M | 3.2M | 2.7M | 2.2M | 2.2M | 2.2M | 2.2M | 2.2M | 2.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Dec 31 | Dec 31 | Sep 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $62.0M | $6.4M | $4.8M | $111.0K | $1.1M | $4.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $1.0M | $7.1M | $3.9M | $5.4M |
| Total assets | $63.4M | $8.5M | $5.3M | $3.0M | $1.7M | $6.0M |
| Total liabilities | $17.0M | $16.1M | $17.2M | $27.3M | $24.3M | $26.1M |
| Shareholders' equity | $46.4M | -$7.6M | -$11.9M | -$24.3M | -$22.6M | -$20.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology